Verastem, Inc. Files 8-K: Officer/Director Changes & Financials
Ticker: VSTM · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $485,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, financials, corporate-governance
TL;DR
Verastem 8-K: Director/officer changes, new appointments, and financial updates filed Jan 21.
AI Summary
Verastem, Inc. filed an 8-K on January 21, 2025, reporting events as of January 14, 2025. The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates potential shifts in Verastem's leadership and governance, which could impact strategic direction and operational focus.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially when combined with financial reporting, can signal internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- January 21, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Needham, MA (location) — Principal Executive Offices
FAQ
What specific officer or director positions were affected by the events reported on January 14, 2025?
The filing indicates the 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers' but does not specify the names or exact positions within this summary.
Are the financial statements included in this 8-K for a specific period?
The filing states 'Financial Statements and Exhibits' are included, but the specific reporting period for these statements is not detailed in the provided text.
What is the primary business of Verastem, Inc.?
Verastem, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
When was Verastem, Inc. incorporated?
Verastem, Inc. was incorporated in Delaware.
What is the main purpose of this Form 8-K filing?
This Form 8-K is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, detailing significant corporate events such as changes in officers/directors and financial reporting.
Filing Stats: 938 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2025-01-21 16:30:28
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
- $485,000 — eceive an initial annual base salary of $485,000 and is eligible for an annual bonus tar
Filing Documents
- tm253996d1_8k.htm (8-K) — 27KB
- tm253996d1_ex10-1.htm (EX-10.1) — 65KB
- 0001104659-25-004918.txt ( ) — 278KB
- vstm-20250114.xsd (EX-101.SCH) — 3KB
- vstm-20250114_lab.xml (EX-101.LAB) — 33KB
- vstm-20250114_pre.xml (EX-101.PRE) — 22KB
- tm253996d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Operating Officer Appointment Effective January 14, 2025, Verastem, Inc. (the "Company") appointed Matthew E. Ros as Chief Operating Officer of the Company. Mr Ros, age 58, has more than 35 years of experience in global pharmaceutical and early-stage biotechnology companies. Mr. Ros served as the Chief Executive Officer and board member at FORE Biotherapeutics, a privately held clinical-stage precision oncology company, from April 2022 to August 2023. Prior to this, Mr. Ros served at Epizyme, Inc., a publicly traded biopharmaceutical company, as Chief Operating Officer between May 2016 and November 2018 and then as Executive Vice President, Chief Strategy and Business Officer from October 2018 to November 2021. Mr. Ros has served as a board member at Cogent Biosciences, Inc. since 2019. He received a B.S. from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University of Pennsylvania. In connection with his appointment, the Company entered into an employment agreement with Mr. Ros (the "Agreement"), dated January 14, 2025. Under the Agreement, Mr. Ros will receive an initial annual base salary of $485,000 and is eligible for an annual bonus target of 45% of his base salary. Pursuant to the terms of the Agreement and subject to the approval of the Company's board of directors, the Company will grant Mr. Ros (i) 50,000 restricted stock units ("RSUs"), to vest as to 25% of the shares on the one-year anniversary of the Grant Date, and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date, and (ii) 33,333 RSUs, with the award to vest based o
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 10.1 Employment Agreement dated January 14, 2025 by and between Verastem, Inc. and Matthew Ros 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: January 21, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson President and Chief Executive Officer